Aims: To look for correlations between expression of cell cycle regulatory proteins p34cdc2, p21WAF1, and p53 in node negative invasive ductal breast carcinoma, or between these proteins and clinicopathological parameters, and to assess their prognostic value.
Methods: Immunohistochemistry using formalin fixed, paraffin wax embedded sections from 94 breast carcinomas. Adjacent benign epithelial breast tissue was available in 74 cases. Median follow up was 72 months.
Results: Nuclear and cytoplasmic p34cdc2 expression was seen in 80 and 62 tumours, respectively; nuclear expression was seen in adjacent benign epithelium in 12 cases. p21WAF1 and p53 were positive in 48 and 21 tumours, respectively. High expression of p34cdc2 in neoplastic nuclei was associated with higher histological grade and p53 expression, but not with tumour size, steroid receptor status, patient age, menopausal status, recurrence, metastasis, disease free survival (DFS), or overall survival (OS). p34cdc2 in tumour cytoplasm was associated with p34cdc2 nuclear positivity, high tumour grade, and DFS in univariate but not multivariate analysis. In contrast, p34cdc2 expression in benign tissue independently predicted DFS and OS in univariate and multivariate analysis. Expression of p53 was associated with high tumour grade and negative steroid receptors, but not with recurrence, metastasis, DFS, or OS. p21WAF1 expression was not associated with the examined parameters.
Conclusions: p34cdc2, p21WAF1, and p53 expression does not predict outcome in node negative breast carcinoma, although p34cdc2 expression in benign tissue is related to prognosis. The association between p34cdc2 and p53 implicates p53 in G2–M cell cycle checkpoint control, possibly via mediators unrelated to p21WAF1.
- breast carcinoma
- bn, benign
- CDK, cyclin dependent kinase
- DFS, disease free survival
- ER, oestrogen receptor
- MPF, mitosis or maturation promoting factor
- OS, overall survival
- PR, progesterone receptor
- TBS, Tris buffered saline
- TC, tumour cytoplasm
- TN, tumour nuclei
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.